A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD

Trial Profile

A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Umeclidinium/vilanterol (Primary) ; Tiotropium bromide; Umeclidinium
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 24 May 2017 Results (n=2251) of an integrated post-hoc safety analysis from NCT01899742, NCT01777334, NCT01316900 and NCT01316913 studies, presented at the 113th International Conference of the American Thoracic Society.
    • 27 Sep 2015 Pooled post-hoc analysis results from this and two other trials (ZEP117115 and DB2113360) presented at the European Respiratory Society (ERS) International Congress, according to a GlaxoSmithKline media release.
    • 27 Sep 2015 Pooled post-hoc analysis results from this and two other trials (ZEP117115 and DB2113360) published in a GlaxoSmithKline media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top